ArticleEMBO molecular medicine2020
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 71 citations in OpenAlex.
- Expanding Synthetic Lethality in DNA Damage Response-Defective Cancers Through Stress Phenotype-Guided Kinase Targeting.International journal of molecular sciences · 2026Review
- Oxidative DNA Damage Is Associated with Immune Remodeling and Therapeutic Response in High-Grade Serous Ovarian Cancer.Cancers · 2026Article
- Molecular classification identifies aggressive gastrointestinal stromal tumor subtype targetable by PARP inhibitors.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications.Translational oncology · 2026Review
- Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair.Molecular cancer · 2026Review
- High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.International journal of molecular sciences · 2026Review
- Metabolomic-driven prediction of the mutational status of healthy individuals with a family history of hereditary breast and ovarian cancer syndrome: the HRRmet study.Scientific reports · 2026Article
- Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer.Cancer research · 2026Article
- Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance.Frontiers in oncology · 2026Review
- Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADPInternational journal of biological sciences · 2026Article
- Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma.Journal of cellular and molecular medicine · 2025Article
- Clinical approaches to overcome PARP inhibitor resistance.Molecular cancer · 2025Review
- Unraveling the nexus: Genomic instability and metabolism in cancer.Cell reports · 2025Review
- Mitochondrial DNA variants in the pathogenesis and metabolic alterations of diabetes mellitus.Molecular genetics and metabolism reports · 2025Review
- Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database.Cancers · 2025Article
- The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities.Neoplasia (New York, N.Y.) · 2024Review
- Interplay between altered metabolism and DNA damage and repair in ovarian cancer.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Human umbilical cord mesenchymal stem cells attenuate diabetic nephropathy through the IGF1R-CHK2-p53 signalling axis in male rats with type 2 diabetes mellitus.Journal of Zhejiang University. Science. B · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 10 institutions in 3 countries.
Álvaro LahigueraProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Petra HyroššováDepartament de Ciències Fisiològiques, Universitat de Barcelona, Barcelona, Spain.
Agnès FiguerasProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Diana GarzónProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Roger MorenoProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Vanessa Soto-CerratoDepartament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Barcelona, Spain.
Iain McNeishDepartment of Surgery and Cancer, Imperial College, London, UK.
Violeta SerraExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.ORCID 0000-0001-6620-1065
Conxi LazaroOncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Pilar BarretinaMedical Oncology Department, Institut Català d'Oncologia, IDIBGI, Girona, Spain.
Joan BrunetCIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Javier MenéndezProgram against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.
Xavier Matias-GuiuOncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
August VidalOncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Alberto VillanuevaProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Barbie Taylor-HardingWomens Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Hisashi TanakaWomens Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sandra OrsulicDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Alexandra JunzaMetabolomics Platform, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Spain.
Oscar YanesMetabolomics Platform, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Spain.
Cristina Muñoz-PinedoCell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Luís PalomeroProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
Miquel Àngel PujanaProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
José Carlos PeralesDepartament de Ciències Fisiològiques, Universitat de Barcelona, Barcelona, Spain.
Francesc ViñalsProgram Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-9918-6751
Institut d'Investigació Biomédica de Bellvitge · ESInstituto de Salud Carlos III · ESUniversitat de Barcelona · ESCedars-Sinai Medical Center · USCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESInstitut Català d'Oncologia · ESBellvitge University Hospital · ESImperial College London · GBUniversitat de Girona · ESUniversity of California, Los Angeles · US
Funding
Mechanisms of gene amplification in human cancersR01CA149385 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI TANAKA, HISASHI · 2010 to 2022
$3.4MGeneralitat de Catalunya (Government of Catalonia) 2017SGR449MEC | Instituto de Salud Carlos III (ISCIII) FIS PI15/00854MEC | Instituto de Salud Carlos III (ISCIII) FIS PI16/01898Ministerio de Economía, Industria y Competitividad, Gobierno de España (MINECO) BFU2015-66030Ministerio de Economía, Industria y Competitividad, Gobierno de España (MINECO) SAF2017-85869-RNCI NIH HHS R01 CA149385
Abstract
Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination-defective (HRD) cancers rely on oxidative metabolism to supply NAD
Indexed as
Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsCarcinoma, Ovarian EpithelialFemaleHomologous RecombinationHumansOxidative StressPoly(ADP-ribose) Polymerase InhibitorsBCRAcancer metabolismmetforminOXPHOSPARP inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.